Tumor Immunity in Neurologically Normal Patients
Observational
Observational Model: Case Control, Time Perspective: Prospective
Assessment of PND antibody titer, CTL activity, and clinical data in neurologically normal patients with SCLC and gynecologic tumors, with tumors unrelated to PNDs, and in normal control patients.
Duration of study
No
Robert Darnell, MD, PHD
Principal Investigator
Rockefeller University
United States: Institutional Review Board
RDA-0269
NCT00481637
March 1998
December 2015
Name | Location |
---|---|
Rockefeller University Hospital | New York, New York 10021-6399 |